Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] Group 1: Corporate Presentation - CEO Brian Lian, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, California [1][2] - The presentation is scheduled for January 12, 2026, from 2:15 to 2:55 p.m. Pacific Time, and will be available via live webcast [2] Group 2: Company Overview - Viking Therapeutics specializes in first-in-class or best-in-class therapies targeting metabolic and endocrine disorders, leveraging expertise in metabolism [3] - The company is advancing VK2735, a dual agonist for GLP-1 and GIP receptors, currently in a Phase 3 obesity program with two trials (VANQUISH-1 and VANQUISH-2) [3] - VK2809, an orally available small molecule for lipid and metabolic disorders, has shown positive results in Phase 2b studies for NASH and fibrosis, and in Phase 2a trials for NAFLD [3] - The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD), which has demonstrated safety and efficacy in reducing VLCFAs in a Phase 1b trial [3]